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V. 1
IntrOductIOn
Warfarin is now the most widely-used anticoagulant in the world. 
In the United Kingdon (UK), it has been estimated that at least 
1% of the whole population is taking warfarin [1]. Although new 
oral anticoagulants are available, warfarin remains a viable oral 
anticoagulant for many patients because of its availability and cost 
[2]. The risk of warfarin-induced bleeding complications is well-
known and is typically managed with vitamin K, which restores the 
production of vitamin K–dependent coagulation factors within 12–
24 hour [3]. The therapeutic range for warfarin therapy is defined 
in terms of the International Normalized Ratio (INR). The INR is 
calculated as the prothrombin time ratio (patient prothrombin 
time/mean of normal prothrombin time for laboratory)ISI, which 
uses the International Sensitivity Index (ISI) for an exponent, and 
is dependent on the specific reagents and instruments used in the 
measurement. For most reagent and instrument combinations in 
current use, the ISI is close to 1, making the INR roughly the ratio 
of the patient prothrombin time to the mean normal prothrombin 
time [4]. Obtaining exact and consistent INR levels maximizes the 
desired benefits and safety of warfarin [5]. The Time in Therapeutic 
Range (TTR) estimates the percentage of time a patient’s INR is 
within the desired treatment range or goal and is widely-used as 
an indicator of anticoagulation control. TTR is commonly used to 
evaluate the quality of warfarin therapy and is an important tool for 
assessing the risks versus benefits of warfarin therapy [6]. There 
are 3 methods for assessing TTR in patients taking warfarin: 1) 
Calculating the fraction of INRs that are in range, which is the 
conventional method; 2) Evaluating a cross-section of the patient's 
files; and 3) using the Rosendaal method [7,8]. Assessing TTR allow 
physicians to estimate the success of warfarin therapy in patients, 
because it is a major determinant of warfarin’s efficacy and safety, 
with the maximum benefits evident when TTR is >70% [6,9]. The 
 
aim of the present study was to evaluate TTR in patients with non-
valvular atrial fibrillation who were receiving warfarin therapy at a 
referral hospital for cardiovascular diseases in Tehran, Iran. 
MAterIAls And MethOds
This cross-sectional study was done during six months (between 
September 2014 to March 2015) at outpatient anticoagulant clinic 
of Shaheed Rajaie Hospital, Tehran, Iran. This is a well-known 
center for the treatment of cardiovascular diseases in Iran. Patients 
diagnosed with non-valvular atrial fibrillation were included in the 
study if they were between 30-85-years-old and had been taking 
warfarin for >3 months. Patients who did not want to participate 
in the study were excluded. All study participants signed consent 
forms after the study procedures were explained. Demographic 
data such as age, sex, educational level, medical history and 
current medications were determined for all participants. The INRs 
of patients were collected during their referral to the clinic where 
every patient had at least 3 INR measurements taken in total. 
Each patient's TTR was calculated using the Rosendaal method. 
The Rosendaal linear interpolation methodology is based on the 
INR-DAY software program (Dr. F.R. Rosendaal, Leiden, The 
Netherlands) that assumes a linear relationship exists between 
two INR values and allows the researcher to allocate a specific 
INR value to each day for each patient [8]. 
stAtIstIcAl AnAlysIs
Results are reported as mean ± SD. Data were analysed using 
the Statistical Package for the Social Sciences version 20 (SPSS-
20), and p-values less than 0.05 were considered statistically 
significant. The continuous data obtained in this study were 
analysed using Chi-square test. Significant univariate predictors 
were subsequently assessed in the multivariate logistic regression 
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ABstrAct
Introduction: Anticoagulant control is assessed by Time in 
Therapeutic Range (TTR). For a given patient, TTR is defined 
as the duration of time in which the patient’s International 
Normalized Ratio (INR) values were within a desired range. 
Aim: To assess TTR in patients receiving treatment with 
warfarin for non-valvular atrial fibrillation at a referral center for 
cardiovascular diseases in Tehran, Iran. 
Materials and Method: Over 6 months, we enrolled eligible 
patients presenting to Shaheed Rajaie Hospital in Tehran for 
regular INR testing. Demographic data, medical history, and 
current medications were determined for all participants. TTR 
was assessed by the Rosendaal method.
results: A total of 470 patients (mean age 58.0±14.2 years, 
60.2% women) underwent 1450 INR measurements. The mean 
TTR was calculated as 54.9±11.9%. Of the sample patients, 
37.3% were in the good control category (TTR > 70%), 24.6% 
were in the intermediate category (50% < TTR < 70%), and 
38.1% were in the poor control category (TTR < 50%). The 
number of current medications above four was a significant 
predictor of poor control (OR = 2.06; 95% CI, 1.87, 2.23). The 
mean TTR of the studied patients (54.9%) was below the good 
control range. 
conclusion: The quality of anticoagulant therapy with warfarin 
in Iranian patients was poorer than that reported in European 
countries. Based on these results, research considering the 
causes of poor TTR among Iranian patients is recommended.
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total good 
control
intermediate 
Control
Poor 
control
p-value
Age < 75 414 152 (36.7%) 103 (24.9%) 159 
(38.4%)
0.42
≥ 75 56 23 (35.7%) 13 (23.2%) 20 (35.7%)
Sex Male 187 74 (36.9%) 40 (21.4%) 73 (39.0%) 0.38
Female 283 101(35.7%) 76 (26.9%) 106 
(37.5%)
Educational 
level
Illiterate 75 27 (36.0%) 17 (22.7%) 31 (41.3%) 0.43
Under 
Diploma
198 79 (39.9%) 45 (22.7%) 74 (34.7%)
Diploma 124 43 (36.3%) 36 (29%) 43 (34.7%)
BS 42 12 (28.6%) 10 (23.8%) 20 (47.6%)
MS 27 10 (37.0%) 7 (25.9%) 10 (37.0%)
Doctorate 
and above
3 2 (66.7) 0(0%) 1 (33.3%)
Marital 
status
Single 145 43 (29.6%) 57 (39.3%) 45 (31.1%) 0.87
Married 325 101(31.1%) 139 (42.8%) 85 (26.1%)
[table/Fig-1]: Demographic parameters of studied patients.
total good 
control
intermediate 
Control
Poor 
control
p-value
Hypertension Yes 142 58 (40.8%) 30 (21.2%) 54 (38%) 0.41
No 328 117 (35.7%) 86 (26.2%) 125 
(38.1%)
DVT Yes 8 1 (12.5%) 1 (12.5%) 6 (75%) 0.11
No 462 174 (37.7%) 115 (24.9%) 173 
(37.4%)
Pulmonary 
Embolism
Yes 6 2 (33.3%) 2 (33.3%) 2 (33.3%) 0.77
No 464 173 (37.3%) 114 (24.6%) 177(38.1%)
Heart Failure Yes 6 3 (50%) 2 (33.3%) 1(16.7%) 0.58
No 464 172 (37.1%) 114 (24.6%) 178 
(38.4%)
Diabetes 
Mellitus
Yes 104 39 (37.5%) 19 (18.3%) 46 (44.2%) 0.16
No 366 136 (37.2%) 97 (26.5%) 133 
(36.3%)
Coronary 
Heart 
Disease
Yes 142 58 (40.8%) 30 (21.1%) 54 (38.0%) 0.41
No 328 117 (35.7%) 86 (26.2%) 125 
(38.1%)
[table/Fig-2]: TTR of studied patients based on medical history.
model to determine their independent effect, expressed as Odds 
Ratio (OR) and 95% Confidence Interval (CI). The p <.05 was 
considered significant.
results
This study involved 470 patients receiving warfarin who participated 
for 6 months. The total number of INR measurements was 1450. 
The mean (±SD) TTR for 470 patients was 54.9 ± 11.9%. The 
stratification of patients according to TTR levels was conducted 
as follows: a TTR level of >70% was considered to represent 
good control, a TTR level between 50% and 70% was considered 
to represent intermediate control, and a TTR level of <50% was 
considered to represent poor control. The good control group 
contained 175 patients (37.3%), 116 patients (24.6%) were in the 
intermediate control group, and 179 patients (38.1%) were in the 
poor control group. The mean age of the sampled patients was 
58.0 ± 14.2 years and 283 (60.2%) were women. The patient 
demographics have been shown in [Table/Fig-1]. As seen in 
[Table/Fig-1], there is no significant difference across the three 
TTR categories in terms of age, sex, educational level, or marital 
status (p = 0.42, 0.38, 0.43, and 0.87, respectively). The TTRs for 
patients with medical histories such as hypertension, deep vein 
thrombosis, pulmonary embolism, heart failure, diabetes mellitus, 
and coronary heart disease were determined. [Table/Fig-2] shows 
the distribution of sampled patients with medical histories in each 
category. Analysis showed that there were not any differences 
between the TTR categories and medical histories. [Table/Fig-3] 
shows the number of current medications taken in each category 
of studied patients. The rate of good control is >85% in patients 
who receive less than 4 medications, but in patients with ≥5 
medications, the rate decreases to <20%. Analysis showed that 
there is a significant difference between TTR categories and number 
of current medications in the evaluated patients, where, by the 
number of poor control patients have increased as the number of 
medications taken increases. To evaluate the independent effects 
of each variable (including demographic parameters, medical 
histories, and number of current medications) as a predictor of 
poor control, we performed a multivariate logistic regression. We 
identified only numbers of medication >4 as significant predictors 
of poor control (OR = 2.06; 95% CI, 1.87, 2.23).
dIscussIOn
Vitamin k antagonists have been shown to be effective in the 
treatment and prevention of thromboembolic events; however 
they possess many drug- drug and drug-food interactions, as well 
as a narrow therapeutic window [10]. The efficacy and safety of 
oral vitamin K antagonists such as warfarin depend strongly on 
the percentage of TTR, with the maximum benefits being evident 
when the TTR is >70% [11,12]. It is well-known that poor control 
of anticoagulant intensity increases the risks of thrombotic and 
haemorrhagic events [9]. The consistency of an effective INR is 
reflected by the TTR, which is a measure of the period in which 
the patient was in an optimal INR range. Cotte et al., evaluated 
the TTRs of 6250 patients in four European countries (France, 
Germany, Italy, and United Kingdom) with atrial fibrillation who 
had been prescribed vitamin K antagonists. They concluded that 
47.8%, 44.2%, 46.1%, and 65.4% of the evaluated patients had 
TTRs >70% in France, Germany, Italy, and the United Kingdom, 
respectively [13]. Our results showed that the percentage of good 
control patients (37.3%) was less than that of each European 
country as discussed by Cotte et al., [13]. 
Mark et al., [14] recently analysed data from 272 patients with 
non-valvular atrial fibrillation in a hospital in Hungary. They did 
not classify their patients into different TTR categories and only 
reported the mean TTR, which was found to be 64%. The mean 
TTR in our study (54.9%) was lower than that reported by Mark 
et al. It seems that Iranian patients have poorer control of warfarin 
dosing compared to the patients in European studies [14]. Our 
results were similar to those from recent research by Zubaid et 
al., in Kuwait. They evaluated the quality of warfarin therapy for 
369 patients with non-valvular atrial fibrillation and estimated TTRs 
by the Rosendaal method. They reported a mean TTR of 52.6% 
in their sample, which is close to the mean TTR determined in 
the present study (54.9%) [15]. Pharmacogenetic and dietary 
regimens are two important factors to be considered in relation to 
warfarin [16-18]. Iran and Kuwait are located in western Asia and 
have similar dietary regimens, cultures and genetic patterns, which 
may provide reasons for why our results and those in Zubaid’s 
study are similar. Zubaid et al., had concluded that females and 
patients with no history of hypertension were more likely to have 
poor anticoagulation (expressed as Rosendaal TTR < 58%). 
number of 
medications
total good 
Control
intermediate 
Control
Poor 
Control
p 
1 8 7 (87.5%) 0 (0%) 1 (12.5%) 0.01
2 33 29 (87.8%) 2 (6.1%) 2 (6.1%)
3 44 38 (86.3%) 4 (9.1%) 2 (4.6%)
4 68 58 (85.3%) 6 (8.8%) 4 (5.9%)
5 128 25 (19.5%) 96 (75.1%) 7 (5.4%)
>6 189 34 (18%) 145 (76.7%) 10 (5.3%)
[table/Fig-3]: Number of current medications in studied patients.
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Unlike Zubaid et al., we did not see any tendencies of poor control 
among females or patients without hypertension. Melamed et al., 
[19] studied TTR in 906 patients diagnosed with atrial fibrillation 
in the United States who were treated with warfarin for at least 
6 months. They concluded that poor control (TTR < 60% in their 
study) was significantly associated with females, advanced age 
(>75 years), and heart failure [19]. However, in our study, there 
were no significant differences in TTR between male and females 
(p = 0.38), patients <75 years, those >75 years (p = 0.42), 
and patients with and without heart failure (p = 0.58). Previous 
studies have not referred to the relationship between TTR and the 
number of patient’s medications. In the present study, a significant 
decrease in good control rates had been observed when the 
patients were prescribed more than 4 medications. It seems that 
the number of prescribed medications may be an important factor 
influencing patient adherence to warfarin therapy that can affect 
TTR indirectly. Zulling et al., evaluated adherence barriers among 
patients with cardiovascular risk factors. The most commonly 
reported medication barrier was having too many medications to 
take (31%), in their study [20]. 
cOnclusIOn
There are no reports in the literature regarding TTR values in Iranian 
patients and this is the first study that evaluates TTR in the Iranian 
population. We found a mean TTR of 54.9% in Iranian patients 
diagnosed with non-valvular atrial fibrillation who were receiving 
warfarin therapy. Only one factor was significantly related to poor 
control among patients: increase in the number of medications 
administered by the patients. In the future, we recommend 
evaluating factors that could possibly affect INR values and TTR 
rates, such as drug-warfarin interactions, food-warfarin interactions 
and patients’ treatment adherence.
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